---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-027032"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2025-07-24T23:59:59+00:00"
generated_at: "2026-05-18T02:04:11.761365+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma restructures, cuts headcount 30%, delays FA/PKD programs; cash runway to Q2 2027

## Summary
- Headcount reduction of ~30% and 12-month cash burn reduction of ~25% as part of corporate reorganization.
- Pipeline focus on AAV cardiovascular programs (Danon, PKP2-ACM, BAG3-DCM) and KRESLADI for severe LAD-I.
- Cash runway extended into Q2 2027; excludes any potential proceeds from Priority Review Voucher for KRESLADI.
- Fanconi Anemia (RP-L102) and Pyruvate Kinase Deficiency (RP-L301) programs delayed; FDA OK for RP-L102 no longer expected in 2026.

## SEC filing metadata
- accession: 0001140361-25-027032
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2025-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036125027032/0001140361-25-027032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036125027032/ef20052552_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-027032
- JSON: https://secwatch.observer/filing/0001140361-25-027032.json
- Plain text: https://secwatch.observer/filing/0001140361-25-027032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.